Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of Q-Cells (Glial-stem-cell-therapy) for the treatment of Transverse Myelitis

Trial Profile

A study of Q-Cells (Glial-stem-cell-therapy) for the treatment of Transverse Myelitis

Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Glial stem cell therapy (Primary)
  • Indications Transverse myelitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2017 New trial record
    • 25 Jul 2017 The U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application to proceed with a Phase 1/2a clinical trial of Q-Cells in patients with Transverse Myelitis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top